Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in EGFR-mutated NSCLC
NCT01667562Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2012
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Primary endpoint: Progression-Free Survival. Started Jan 2012; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01667562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01667562.